Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $48.20

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $48.20.

Several analysts have weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a research note on Thursday, August 15th. Chardan Capital reissued a “buy” rating and issued a $53.00 target price on shares of Outlook Therapeutics in a research note on Friday, August 16th. Ascendiant Capital Markets reduced their price target on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd. Finally, BTIG Research reiterated a “buy” rating and issued a $50.00 price objective on shares of Outlook Therapeutics in a research report on Friday, October 18th.

Outlook Therapeutics Trading Up 5.0 %

Shares of NASDAQ OTLK opened at $6.05 on Wednesday. The stock’s 50-day moving average is $6.07 and its 200 day moving average is $7.17. The stock has a market cap of $143.14 million, a price-to-earnings ratio of -0.54 and a beta of 0.62. Outlook Therapeutics has a 1-year low of $4.61 and a 1-year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.23. On average, analysts forecast that Outlook Therapeutics will post -3.63 EPS for the current fiscal year.

Insider Buying and Selling at Outlook Therapeutics

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon acquired 5,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were purchased at an average cost of $5.69 per share, for a total transaction of $28,450.00. Following the transaction, the chief financial officer now owns 5,946 shares in the company, valued at $33,832.74. This represents a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 3.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Outlook Therapeutics

A number of large investors have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the second quarter worth about $75,000. Christensen King & Associates Investment Services Inc. bought a new position in shares of Outlook Therapeutics in the 3rd quarter worth approximately $55,000. Squarepoint Ops LLC purchased a new position in shares of Outlook Therapeutics in the 2nd quarter valued at approximately $232,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at approximately $303,000. Finally, LVW Advisors LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at approximately $352,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.